# OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

> **NCT00449722** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 380 (—)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** mesalazine

## Key facts

- **NCT ID:** NCT00449722
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 380 (—)
- **Last updated:** 2016-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449722, "OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00449722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*